Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
OCS is expected to report earnings to fall 19.67% to -39 cents per share on August 06
Q2'26
Est.
$-0.39
Q1'26
Beat
by $0.08
Q3'25
Beat
by $0.14
Q2'25
Missed
by $0.03
Q1'25
Missed
by $0.23
The last earnings report on May 11 showed earnings per share of -49 cents, beating the estimate of -56 cents. With 772.60K shares outstanding, the current market capitalization sits at 677.55M.